These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Hiles JJ; Kolesar JM Am J Health Syst Pharm; 2008 Jan; 65(2):123-31. PubMed ID: 18192256 [TBL] [Abstract][Full Text] [Related]
24. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. Hutson TE; Escudier B; Esteban E; Bjarnason GA; Lim HY; Pittman KB; Senico P; Niethammer A; Lu DR; Hariharan S; Motzer RJ J Clin Oncol; 2014 Mar; 32(8):760-7. PubMed ID: 24297950 [TBL] [Abstract][Full Text] [Related]
25. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771 [TBL] [Abstract][Full Text] [Related]
26. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Fogli S; Porta C; Del Re M; Crucitta S; Gianfilippo G; Danesi R; Rini BI; Schmidinger M Cancer Treat Rev; 2020 Mar; 84():101966. PubMed ID: 32044644 [TBL] [Abstract][Full Text] [Related]
27. Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer. Date E; Okamoto K; Fumita S; Kaneda H Invest New Drugs; 2018 Apr; 36(2):350-353. PubMed ID: 29018997 [TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report. Tori M; Shimo T BMC Cancer; 2018 Jun; 18(1):698. PubMed ID: 29954369 [TBL] [Abstract][Full Text] [Related]
29. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors. Lee NR; Yhim HY; Yim CY; Kwak JY; Song EK Ann Pharmacother; 2011 Oct; 45(10):e56. PubMed ID: 21954449 [TBL] [Abstract][Full Text] [Related]
30. Clinical Characteristics Associated With Lenvatinib-induced Fistula and Tumor-related Bleeding in Patients With Thyroid Cancer. Staub Y; Nishiyama A; Suga Y; Fujita M; Matsushita R; Yano S Anticancer Res; 2019 Jul; 39(7):3871-3878. PubMed ID: 31262915 [TBL] [Abstract][Full Text] [Related]
31. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib. Papadimitriou M; Papadimitriou CA Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262 [TBL] [Abstract][Full Text] [Related]
32. Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions. Cabanillas ME; Hu MI; Jimenez C J Clin Endocrinol Metab; 2014 Dec; 99(12):4390-6. PubMed ID: 25238206 [TBL] [Abstract][Full Text] [Related]
33. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib. Zhou A; Zhang W; Chang C; Chen X; Zhong D; Qin Q; Lou D; Jiang H; Wang J Cancer Chemother Pharmacol; 2013 Nov; 72(5):1043-53. PubMed ID: 24043137 [TBL] [Abstract][Full Text] [Related]
35. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441 [TBL] [Abstract][Full Text] [Related]
36. Lenvatinib: first global approval. Scott LJ Drugs; 2015 Apr; 75(5):553-60. PubMed ID: 25795101 [TBL] [Abstract][Full Text] [Related]
37. Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Coriat R; Ropert S; Mir O; Billemont B; Chaussade S; Massault PP; Blanchet B; Vignaux O; Goldwasser F Invest New Drugs; 2011 Oct; 29(5):1090-3. PubMed ID: 20524036 [TBL] [Abstract][Full Text] [Related]
38. Kinase Inhibitors in Multitargeted Cancer Therapy. Gentile C; Martorana A; Lauria A; Bonsignore R Curr Med Chem; 2017; 24(16):1671-1686. PubMed ID: 28078996 [TBL] [Abstract][Full Text] [Related]
39. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553 [TBL] [Abstract][Full Text] [Related]
40. Risk of arterial thrombosis not increased by sorafenib or sunitinib. Minor DR J Clin Oncol; 2010 Oct; 28(30):e619; author reply e620. PubMed ID: 20733133 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]